Dr. Prashant Singh made headlines in FSU News this week when he was awarded funding for his E. coli research. The FSU Office of Commercialization awarded approximately $73,000 to faculty for the Fall 2020 GAP Commercialization Investment Program. The program is designed to help FSU researchers realize the commercial potential for their work. Dr. Singh has developed a procedure that distinguishes between virulent and avirulent strains of E. coli. He will use the funding to validate his procedure and apply for certification from an international organization that regulates tests for foodborne pathogens, which is essential for commercialization. For more information and to read the full article visit news.fsu.edu.